Accesswire
04 Jun 2026, 12:40 UTC · 2h ago
Search tags
Story key points
3 claims · impact-rated
The Israeli Ministry of Health approved an exploratory clinical study of DNase I in combination with anti-CD19 CAR T cells for large B-cell lymphoma (LBCL). — Regulatory approval to move from preclinical to clinical stages is a major value inflection point for a biopharmaceutical company.
+0.60Preclinical results showed that combining DNase I with CAR T cells significantly improved tumor control, delayed relapse, and prolonged survival in leukemia and lymphoma models. — Strong preclinical data provides the fundamental thesis for the drug's potential efficacy, reducing the perceived risk of the upcoming trial.
+0.40The clinical study will treat 12 LBCL patients with stable or progressive disease, targeting a high-risk group with historically low 1-year progression-free survival (20-30%). — Targeting a high-unmet-need population can lead to more dramatic efficacy signals if successful, though the small sample size limits immediate market scale.
+0.30Continue reading
6 related stories
Ticker attribution
Model heads
The company's collaboration partner received regulatory approval for a clinical study following strong positive preclinical results.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
3 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Market Watch
3d ago
